CN1191362C - 新颖的链球菌抗原 - Google Patents

新颖的链球菌抗原 Download PDF

Info

Publication number
CN1191362C
CN1191362C CNB998149047A CN99814904A CN1191362C CN 1191362 C CN1191362 C CN 1191362C CN B998149047 A CNB998149047 A CN B998149047A CN 99814904 A CN99814904 A CN 99814904A CN 1191362 C CN1191362 C CN 1191362C
Authority
CN
China
Prior art keywords
seq
bvh
polypeptide
present
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998149047A
Other languages
English (en)
Chinese (zh)
Other versions
CN1332803A (zh
Inventor
乔西·汉梅尔
伯纳德·R·布罗迪尔
伊沙贝尔·派纽
丹尼斯·马丁
克莱蒙特·里奥斯
娜莎莉·查兰得
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1191362(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Publication of CN1332803A publication Critical patent/CN1332803A/zh
Application granted granted Critical
Publication of CN1191362C publication Critical patent/CN1191362C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNB998149047A 1998-12-23 1999-12-20 新颖的链球菌抗原 Expired - Fee Related CN1191362C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
US60/113,800 1998-12-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100037492A Division CN100398653C (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原
CNA2007101481600A Division CN101134775A (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原

Publications (2)

Publication Number Publication Date
CN1332803A CN1332803A (zh) 2002-01-23
CN1191362C true CN1191362C (zh) 2005-03-02

Family

ID=22351610

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2007101481600A Pending CN101134775A (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原
CNB998149047A Expired - Fee Related CN1191362C (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原
CNB2005100037492A Expired - Fee Related CN100398653C (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2007101481600A Pending CN101134775A (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100037492A Expired - Fee Related CN100398653C (zh) 1998-12-23 1999-12-20 新颖的链球菌抗原

Country Status (29)

Country Link
EP (2) EP1141306B1 (enExample)
JP (2) JP4761623B2 (enExample)
KR (4) KR100891398B1 (enExample)
CN (3) CN101134775A (enExample)
AP (1) AP2001002199A0 (enExample)
AR (1) AR029322A1 (enExample)
AT (1) ATE394489T1 (enExample)
AU (1) AU1764900A (enExample)
BR (1) BR9916477A (enExample)
CA (1) CA2356836C (enExample)
CL (1) CL2009002037A1 (enExample)
CY (3) CY1108223T1 (enExample)
CZ (2) CZ302790B6 (enExample)
DE (1) DE69938670D1 (enExample)
DK (3) DK1141306T3 (enExample)
EA (1) EA007409B1 (enExample)
ES (3) ES2306528T3 (enExample)
HU (1) HU229664B1 (enExample)
IL (3) IL143905A0 (enExample)
MX (1) MXPA01006427A (enExample)
NO (1) NO330800B1 (enExample)
NZ (1) NZ512574A (enExample)
OA (1) OA11736A (enExample)
PL (3) PL205041B1 (enExample)
PT (3) PT1141306E (enExample)
TR (2) TR200200633T2 (enExample)
UY (1) UY25877A1 (enExample)
WO (1) WO2000039299A2 (enExample)
ZA (1) ZA200105114B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757697A3 (en) 1998-02-20 2007-05-30 ID Biomedical Corporation Group B streptococcus antigens
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
DK1141306T3 (da) * 1998-12-23 2008-08-18 Id Biomedical Corp Streptococcus-antigener
ATE412673T1 (de) 2000-06-12 2008-11-15 Univ Saskatchewan Chimäres gapc protein aus streptococcus und dessen verwendung zur impfung und diagnostik
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
EP1303612A2 (en) * 2000-06-20 2003-04-23 Shire Biochem Inc. Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
JP4374245B2 (ja) * 2001-07-06 2009-12-02 アイディー バイオメディカル コーポレイション グループｂ連鎖球菌の抗原及び対応するｄｎａ断片
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
WO2003054007A2 (en) * 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
PT1601770E (pt) * 2003-03-04 2009-12-07 Intercell Ag Antigénios de streptococcus pyogenes
AU2004230244B2 (en) 2003-04-15 2011-09-22 Intercell Ag S. pneumoniae antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
HRP20151122T1 (hr) 2007-06-26 2015-11-20 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae
WO2009012588A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
EP2665490B1 (en) * 2011-01-20 2020-03-04 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
US10161940B2 (en) * 2012-01-05 2018-12-25 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US20160324949A1 (en) 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
AU2016295566B2 (en) 2015-07-21 2019-06-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA3148824A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2025508749A (ja) 2022-01-13 2025-04-10 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250312433A1 (en) 2022-05-11 2025-10-09 Pfizer Inc. Process for Producing of Vaccine Formulations With Preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250169621A (ko) 2023-04-14 2025-12-03 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0656014B1 (en) * 1993-03-19 2003-05-14 LINDAHL, Gunnar Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
EP0832238A1 (en) * 1995-06-07 1998-04-01 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
DK0942983T4 (en) * 1996-10-31 2014-12-01 Human Genome Sciences Inc Streptococcus pneumoniae antigens and vaccines
CN1291233A (zh) * 1997-09-24 2001-04-11 美国明尼苏达州大学 来自肺炎链球菌之人类补体c3降解蛋白酶
CA2328399A1 (en) * 1998-04-23 1999-10-28 University Of Alabama At Birmingham Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
JP2002521058A (ja) * 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
CN1352691A (zh) * 1998-09-24 2002-06-05 美国明尼苏达州大学 来自肺炎链球菌的人补体c3降解性多肽
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
DK1141306T3 (da) * 1998-12-23 2008-08-18 Id Biomedical Corp Streptococcus-antigener

Also Published As

Publication number Publication date
PL205041B1 (pl) 2010-03-31
CN1332803A (zh) 2002-01-23
PT2261358E (pt) 2014-07-30
KR100802198B1 (ko) 2008-02-11
HK1118575A1 (en) 2009-02-13
ES2400280T3 (es) 2013-04-08
KR20080036666A (ko) 2008-04-28
PT1950302E (pt) 2013-01-16
PL206576B1 (pl) 2010-08-31
CY1108223T1 (el) 2014-02-12
PL349777A1 (en) 2002-09-09
WO2000039299A2 (en) 2000-07-06
ES2480417T3 (es) 2014-07-28
AR029322A1 (es) 2003-06-25
DK2261358T3 (da) 2014-07-28
ES2306528T3 (es) 2008-11-01
UY25877A1 (es) 2000-08-21
DK1950302T3 (da) 2013-01-14
CN100398653C (zh) 2008-07-02
NZ512574A (en) 2004-03-26
HU229664B1 (en) 2014-04-28
IL194230A (en) 2013-12-31
ATE394489T1 (de) 2008-05-15
HUP0104774A2 (hu) 2002-04-29
CN101134775A (zh) 2008-03-05
CZ302790B6 (cs) 2011-11-09
BR9916477A (pt) 2004-06-22
PT1141306E (pt) 2008-07-30
OA11736A (en) 2005-06-12
CY1114722T1 (el) 2016-10-05
KR101170203B1 (ko) 2012-07-31
EP1141306A2 (en) 2001-10-10
NO20013045D0 (no) 2001-06-19
KR20100063814A (ko) 2010-06-11
EP2261358A2 (en) 2010-12-15
JP2010142246A (ja) 2010-07-01
KR101078919B1 (ko) 2011-11-01
ZA200105114B (en) 2002-11-21
JP4761623B2 (ja) 2011-08-31
HUP0104774A3 (en) 2007-10-29
CZ20012161A3 (cs) 2001-10-17
DE69938670D1 (de) 2008-06-19
NO20013045L (no) 2001-08-20
CA2356836C (en) 2011-09-13
KR20060134227A (ko) 2006-12-27
AU1764900A (en) 2000-07-31
KR100891398B1 (ko) 2009-04-02
CZ303675B6 (cs) 2013-02-27
TR200102497T2 (tr) 2002-01-21
WO2000039299A3 (en) 2000-11-02
CA2356836A1 (en) 2000-07-06
MXPA01006427A (es) 2002-06-04
IL143905A (en) 2011-05-31
CL2009002037A1 (es) 2010-06-25
IL143905A0 (en) 2002-04-21
PL204073B1 (pl) 2009-12-31
EP2261358B1 (en) 2014-05-14
EP2261358A3 (en) 2011-02-23
JP2002533123A (ja) 2002-10-08
AP2001002199A0 (en) 2001-09-30
IL194230A0 (en) 2011-08-01
EP1141306B1 (en) 2008-05-07
DK1141306T3 (da) 2008-08-18
KR20010104693A (ko) 2001-11-26
CY1115340T1 (el) 2017-01-04
CN1654657A (zh) 2005-08-17
TR200200633T2 (tr) 2002-06-21
EA007409B1 (ru) 2006-10-27
EA200100565A1 (ru) 2002-04-25
JP5039802B2 (ja) 2012-10-03
NO330800B1 (no) 2011-07-18

Similar Documents

Publication Publication Date Title
CN1191362C (zh) 新颖的链球菌抗原
CN1268745C (zh) B组链球菌抗原
CN1449446A (zh) 链球菌抗原
CN1200731C (zh) 用作疫苗的肺炎球菌胆碱结合蛋白衍生物
CN1246038C (zh) 全身性送递肉毒杆菌毒素口服疫苗
CN1201818C (zh) 疫苗
CN1159441C (zh) 粘膜炎莫拉菌的uspa1和uspa2抗原
CN1473166A (zh) 犬埃里希体的同源28kD免疫优势蛋白质基因及其用途
CN1461308A (zh) 基于亮氨酸的基序和梭菌神经毒素
CN1141060A (zh) 嗜血杆菌属转铁蛋白受体基因
CN1259522A (zh) 新颖的来自大叶性肺炎放线杆菌的蛋白质
US6197929B1 (en) Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine
CN1215167C (zh) 幽门螺杆菌活疫苗
CN1934240A (zh) 减毒的革兰氏阴性细菌
CN1245512C (zh) 含重组菌毛蛋白的抗淋病奈瑟氏球茵或脑膜炎奈瑟氏球菌的疫苗
CN1211487C (zh) 链球菌毒素a突变体及其使用方法
CN1246799A (zh) 关于幽门螺杆菌的核酸序列和氨基酸序列及其疫苗组合物
CN1198918C (zh) 减毒的活胸膜肺炎放线杆菌
CN101031647A (zh) 在大肠杆菌中制备猪丹毒杆菌表面保护性抗原变体的方法
CN1191851C (zh) 包含胆碱结合蛋白an－末端截取物的氨基酸的多肽、由该多肽衍生的疫苗及其应用
CN1653084A (zh) 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体
CN1906210A (zh) 表面定位的空肠弯曲杆菌多肽
CN1210401C (zh) 源自粘膜炎莫拉氏菌的化合物
CN1198931C (zh) 粘膜炎莫拉氏菌basb034多肽及应用
CN1631438A (zh) 人和易感动物0157菌基因工程多价亚单位疫苗及制备方法

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: YIDE BIOLOGICAL MEDICAL CO.,LTD.

Free format text: FORMER OWNER: SHIRE BIOCHEM INC

Effective date: 20050513

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20050513

Address after: Columbia Canada

Patentee after: ID BIOMEDICAL Corp.

Address before: Quebec

Patentee before: Shire Biochem Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1091439

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: ID BIOMEDICAL CORP. OF QUEBEC

Free format text: FORMER OWNER: IAF BIOCHEM INT

Effective date: 20130418

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Vancouver, Columbia, Canada, Great Britain

Patentee after: ID BIOMEDICAL Corp.

Address before: Columbia Canada

Patentee before: ID BIOMEDICAL Corp.

TR01 Transfer of patent right

Effective date of registration: 20130418

Address after: Quebec

Patentee after: ID BIOMEDICAL CORPORATION OF QUEBEC

Address before: Vancouver, Columbia, Canada, Great Britain

Patentee before: ID BIOMEDICAL Corp.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050302

Termination date: 20151220

EXPY Termination of patent right or utility model